Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
MMED Catalyst Timeline
Dated clinical, regulatory and corporate events for MiniMed Group, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MiniMed Group, Inc.
Upcoming catalysts 2
Event history 23
Past FDA Catalysts and PDUFA Decisions
How MMED actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every MMED program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MiniMed™ 780G system | type 1 diabetes | 2026-05-21 | Instinct: Time in Range 79.1 %, Hb A1c 6.7 %, Mean Sensor Glucose 137.9 mg/dL, Time in Auto Mode 90.0 %; Simplera Sync: Time in Range 80.6 %, Hb A1c 6.8 %, Mean Sensor Glucose 139.5 mg/dL, Time in Auto Mode 92.6 %Read More | New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G SystemRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wills Courtney NelsonOfficer (SVP, Gen. Counsel, Corp. Sec.) | Grant/Award | 60,730 116,089 held | $0.00 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MMED
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.4 % | 25.70 M | 1.32 M |
Ownership Trends
MMED Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How MMED ranks across every disease it competes in
MMED News
MiniMed Launches MiniMed Flex™, its Smallest and Most Discrete Insulin Pump, in Europe
MiniMed has launched the MiniMed Flex™, its smallest and most discreet insulin pump, in Europe. This app-controlled system features a screenless design and the SmartGuard™ algorithm, aiming to simplify diabetes management. The pump is compact, holds up to 300 units of insulin, and is designed for users aged two and older. It is gradually rolling out across European markets.
Read more →FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions
MiniMed received FDA clearance for MiniMed Fit™, the first tubeless insulin pump. This device offers up to seven days of wear and a 300-unit insulin capacity. It features SmartGuard technology for automated insulin delivery, aiming to simplify diabetes management. The launch is set for spring 2027, following an early customer experience phase.
Read more →MiniMed to Participate in Upcoming Investor Conferences
MiniMed announced that CFO Chad Spooner will participate in several upcoming investor conferences in December 2026. The conferences include the Evercore Healthcare Conference, Citi's Global Healthcare Conference, and Piper Sandler's Annual Healthcare Conference. Live webcasts will be available on the company's Investor Relations website.
Read more →MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results
MiniMed will report its second quarter financial results for fiscal year 2027 on November 24, 2026. The results will be available via a news release at 3:45 a.m. PST, followed by a webcast at 5:30 a.m. PST. The company has a long-standing commitment to advancing diabetes therapies.
Read more →MiniMed Appoints Dr. David Segal as Chief Medical Officer
MiniMed has appointed Dr. David Segal as Chief Medical Officer, succeeding Dr. Robert Vigersky. Dr. Segal brings over 20 years of experience in diabetes care and digital health. He aims to enhance diabetes management through technology, focusing on proactive and personalized care. Dr. Vigersky will transition to Chief Medical Officer Emeritus ahead of his retirement in 2027.
Read more →MiniMed Announces Board of Directors for its Next Chapter as an Independent Company
MiniMed has announced its new Board of Directors following its separation from Medtronic. The board, led by Kevin E. Lofton, includes experienced professionals from various sectors, focusing on growth and innovation in diabetes technology. CEO Que Dallara emphasized the mission to simplify diabetes management for users. This transition marks a significant step for MiniMed as an independent company.
Read more →MiniMed Completes Separation from Medtronic
MiniMed has successfully completed its separation from Medtronic, marking its first day as an independent entity. CEO Que Dallara expressed gratitude for Medtronic's support and emphasized the new freedom to make impactful decisions for diabetes care. The separation involved an exchange of shares, resulting in Medtronic no longer holding equity in MiniMed.
Read more →Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes
A recent six-month randomized trial demonstrated that individuals with type 1 diabetes using the MiniMed Smart MDI system who responded more frequently to alerts had improved glucose outcomes. Specifically, higher responders experienced an average of 8.1 percentage points more Time in Range and a 0.6 percentage point reduction in HbA1c. The findings were presented at the European Association for the Study of Diabetes meeting.
Read more →MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
MiniMed has appointed Sheila Denton as General Counsel and Corporate Secretary. Denton, who has over 25 years of experience in the pharmaceutical and biotech sectors, will support the company's growth as it operates as an independent public entity. She succeeds Courtney Nelson Wills and is expected to enhance MiniMed's strategic direction.
Read more →MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement
MiniMed has filed a Form S-4 Registration Statement with the SEC as part of Medtronic's exchange offer for MiniMed shares. Medtronic aims to exchange up to 225 million shares of MiniMed common stock for its ordinary shares. This move marks the final stage of MiniMed's separation from Medtronic, allowing for greater autonomy in operations.
Read more →MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
MiniMed reported a strong start to fiscal year 2027 with net sales of $843 million, reflecting a 17% increase. The company experienced accelerated U.S. growth of 13% and robust international growth of 18%. MiniMed's innovation pipeline is ahead of schedule, with significant advancements including FDA submissions and new product launches. The company has raised its organic revenue growth guidance for the fiscal year.
Read more →MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor
MiniMed announced that its Flex insulin pump is now shipping with the Instinct sensor. The system allows users to wear the sensor for up to 15 days. Real-world data from the similar 780G system showed users achieved 80 percent time in range. This combination aims to reduce the daily burden of diabetes management.
Read more →MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries
MiniMed has announced that its MiniMed Flex™ insulin pump system is now available to Medicare and Medicare Advantage beneficiaries. This compact, app-controlled device is designed to simplify diabetes management and improve quality of life. The system utilizes SmartGuard™ technology, which automatically adjusts insulin delivery, and has shown positive outcomes in previous studies. The availability of this technology is expected to benefit more individuals living with diabetes.
Read more →MiniMed to Announce Its Fiscal Year 2027 First Quarter Financial Results
MiniMed (Nasdaq: MMED) announced its upcoming financial results for the first quarter of fiscal year 2027, set to be released on September 1, 2026. The results will be accompanied by a webcast discussion, providing insights into the company's performance. MiniMed continues to innovate in diabetes technology, enhancing the lives of those managing diabetes.
Read more →MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
MiniMed has appointed David Endicott, CEO of Alcon, and Linnea Burman to its Board of Directors, expanding the board from nine to eleven members. Endicott's experience in scaling healthcare businesses will be valuable as MiniMed continues its journey as an independent company. Burman, from Medtronic, adds further expertise to the board.
Read more →MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes
MiniMed launched Instinct sensors in Europe, expanding choice for its automated insulin delivery systems. The company states that glycemic outcomes remain virtually identical when using the new Abbott-made sensors compared to existing options. This integration allows patients to access proven clinical performance with greater flexibility in their diabetes management tools.
Read more →MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.
MiniMed launched its smallest app-controlled insulin pump, the MiniMed Flex, in the United States. The device pairs with the Simplera Sync sensor to manage diabetes for type 1 and insulin-requiring type 2 patients. Real-world results show an 80% time in range with recommended settings. The system holds 300 units of insulin and is FDA cleared for users aged seven and older.
Read more →MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results Provides Fiscal Year 2027 Outlook
MiniMed reported strong financial results for the fourth quarter and full year of fiscal 2026, with net sales reaching $837 million, representing a 16% increase. For the first time, the company's annual net sales surpassed $3 billion, with a 14% overall growth. Positive market response is driven by the adoption of the MiniMed 780G system and successful product launches, including MiniMed Flex and MiniMed Go. Looking ahead, MiniMed projects approximately 10% organic revenue growth for fiscal year 2027, supported by new product offerings and expansion in both U.S. and international markets.
Read more →MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott
MiniMed has announced an expanded agreement with Abbott to develop dual glucose-ketone sensors that will integrate with MiniMed's smart dosing systems. This collaboration aims to enhance diabetes management by enabling early detection of rising ketones, which can help prevent diabetic ketoacidosis (DKA). The sensors are designed to be the same size as the existing Instinct sensor and will provide users with additional safety features. Regulatory updates and commercialization details are expected in the coming months.
Read more →